The Indian arm of Japan-based Astellas Pharma Inc. has revealed its plan and commitment to enter the Indian market.

Astellas Pharma India Private Limited aims to establish business with a capitalization of around JPY (Japanese Yen) 32 crore in the Indian market, through developing sales and marketing activities of in-house products.

Astellas plans to first introduce its flagship product 'Prograf' in the domestic market. The drug is used in prevention and treatment of organ rejection after liver and kidney transplants.

Astellas engages in the manufacture, marketing, and import/export of pharmaceuticals products in Japan. The company primarily focuses on the development of products in the areas of urology, immunology and allergy, cardiovascular and diabetes, gastrointestinal and motor organs, infectious diseases, and central nervous system.

The firm primarily operates in Japan, North America, Europe, and Asia.